Celldex Therapeutics Inc.

10/25/2024 | Press release | Distributed by Public on 10/25/2024 06:12

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.